Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 5 / Drugs : 11 - (DrugBank : 7) / Drug target genes : 25 - Drug target pathways : 31

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

Allopregnanolone
   Randi J. Hagerman, MD
      2015   Phase 2   NCT02603926   United States
Citocoline
   Rush University Medical Center
      2015   Phase 2   NCT02197104   United States
Clinical observation
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Corticotropin-releasing hormone
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Cyclophosphamide
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Laboratory biomarker analysis
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Magnetic resonance imaging
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Memantine
   University of California, Davis
      2007   -   NCT00584948   United States
Prednisone
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Sulforaphane
   University of California, Davis
      2021   -   NCT05233579   United States
Therapeutic immune globulin
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States